GlassScriptPhysician profile
Michael C Allemand
NPI 1164408688
$1,512.64
in general payments reported to CMS, 2019-2025
10 companies · $449 in 2025
The $449 reported for 2025 was more than what 86% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $94.30 · 2021: $166 · 2022: $325 · 2023: $240 · 2024: $49.33 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.59 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $388.33 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $343.57 | 2019-2024 | Menopur |
| Medtronic, INC. | $304.99 | 2021-2023 | Truclear |
| Organon LLC | $181.14 | 2021-2025 | |
| Hologic Sales and Service, LLC | $176.58 | 2022-2023 | Btx |
| Kerecis Limited | $34.55 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Merck Sharp & Dohme LLC | $31.90 | 2019 | |
| Abbvie INC. | $22.71 | 2019 | |
| Emd Serono, INC. | $15.65 | 2019 | |
| Coopersurgical, INC. | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Allemand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.